Biomm is a biopharmaceutical company founded in 2001 following Biobrás’ partial spin off, at the time the fourth largest producer of insulin in the world and the largest national producer.
Over the past few years the Company has invested in the improvement of its technology, enhancing its production process and expanding its portfolio.
Recently, the Company has decided to restart the national production of insulin and is implementing a modern industrial unit in Nova Lima, Minas Gerais, designed to produce not only insulin but also other biopharmaceutical products.
Biomm S.A. is listed on the BM&FBOVESPA (Bovespa+) – BIOM3, and has corporate governance practices modelled on the best criteria of transparency, control and decision-making used in the market.
The Company has an experienced technical team that is a pioneer in Brazil in pharmaceutical biotechnology, combined with results-oriented executives who work in competitive environments.
With more than 20 patents and relevant international experience, Biomm is one of the leading Brazilian biotechnology companies.
Last Update on May 28, 2021